Tacrolimus is under clinical development by Marinomed Biotech and currently in Phase II for Allergic Rhino-Conjunctivitis. According to GlobalData, Phase II drugs for Allergic Rhino-Conjunctivitis have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tacrolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tacrolimus overview

Tacrolimus is under development for the treatment of allergic rhino conjunctivitis and herpetic stromal keratitis. The drug candidate is administered through the ophthalmic route. Tacrolimus is formulated as eye drops and acts by targeting calcineurin. The drug candidate is developed based on Marinosolv technology.

It was also under development for dry eye.

Marinomed Biotech overview

Marinomed Biotech (Marinomed) is a biopharmaceutical company which discovers and develops medicines based on patent protected technology platforms in the field of respiratory and ophthalmic diseases. Its proprietary anti-viral technology platform Carragelose, an active anti-viral compound that targets different respiratory virus strains based on polymers derived from red seaweed. Marinomed’s Marinosolv is an anti-allergy compound, which provides an alternative for corticosteroids and anti-histamines. Its OTC products find application in the treatment of asthma, influenza, allergy, allergic rhinitis and chronic obstructive pulmonary disease, among others. It works in partnership with other academic and commercial organizations for the development and commercialization of its products for respiratory and ocular disorders. The company is a spin-off from University of Veterinary Medicine, Vienna. Marinomed is headquartered in Vienna, Austria.

For a complete picture of Tacrolimus’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.